These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32007639)

  • 21. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
    Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
    Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab.
    Sánchez LM; George A; Friend BD; Bhar S; Sasa G; Doherty EE; Craddock J; Steffin D; Salem B; Yassine K; Omer B; Martinez C; Leung K; Krance RA; John TD
    Pediatr Hematol Oncol; 2024 May; 41(4):260-272. PubMed ID: 38131101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study.
    Hong X; Chen Y; Lu J; Lu Q
    Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
    Krishnamurti L; Kharbanda S; Biernacki MA; Zhang W; Baker KS; Wagner JE; Wu CJ
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1270-8. PubMed ID: 18940682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
    Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
    J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
    Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
    Chopra Y; Acevedo K; Muise A; Frost K; Schechter T; Krueger J; Ali M; Chiang KY; Kim VH; Grunebaum E; Wall D
    Transplant Cell Ther; 2024 May; 30(5):546.e1-546.e7. PubMed ID: 38458476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
    Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
    Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
    Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
    Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
    Vignon M; Andreoli A; Dhédin N; Lengliné E; Masson E; Robin M; Granier C; Larghero J; Schlageter MH; de Latour RP; Socié G; Boissel N
    J Adolesc Young Adult Oncol; 2017 Jun; 6(2):299-306. PubMed ID: 27983886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
    Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion.
    Nikoloudis A; Buxhofer-Ausch V; Aichinger C; Binder M; Hasengruber P; Kaynak E; Wipplinger D; Milanov R; Strassl I; Stiefel O; Machherndl-Spandl S; Petzer A; Weltermann A; Clausen J
    Cytotherapy; 2024 May; 26(5):490-497. PubMed ID: 38385908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Haematopoietic Stem Cell Transplantation in Beta Thalassemia Major with Fully Matched Parents as Donor.
    Kerio AA; Shahbaz N; Khattak TA; Ghafoor T; Farhan M; Khan H
    J Coll Physicians Surg Pak; 2024 Mar; 34(3):279-283. PubMed ID: 38462861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.